Synergy Pharmaceuticals Inc

Synergy Pharmaceuticals — Leerink Partners Global Healthcare Conference 2018

8 slides from Synergy Pharmaceuticals's conference presentation, Feb 15, 2018

  1. Slide 1: Safe Harbor Statement

    SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting contain forward-looking statements related to Synergy Pharmaceuticals Inc. under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subjec

  2. Slide 2: 2018 Key Business Priorities

    2018 KEY BUSINESS PRIORITIES 3 Optimizing the value of Trulance Continuing to grow market share in CIC Expanding Trulance use with new IBS-C indication Pulling-through market access wins and expanding coverage Ensuring a strong financial foundation Achieving cost efficiencies and prioritizing invest

  3. Slide 3: Trulance prescription volume growing consistently since launch

    TRULANCE PRESCRIPTION VOLUME GROWING CONSISTENTLY SINCE LAUNCH 4 TRX - 30-Count Packs Source: IQVIA, Mar – Dec 2017 0 2000 4000 6000 8000 10000 12000 14000 16000 18000 TRx Extended Unit TRx Trulance 2017 Monthly TRx Volume

  4. Slide 4: Trulance 'pills per Rx' increasing steadily since launch

    Trulance ‘pills per Rx’ increasing steadily since launch 5 Source: IQVIA, Mar – Dec 2017 30.0 31.0 32.0 33.0 34.0 35.0 36.0 37.0 38.0 39.0 40.0 Mar 2017 Apr 2017 May 2017 Jun 2017 Jul 2017 Aug 2017 Sep 2017 Oct 2017 Nov 2017 Dec 2017 Pills per Prescription Trulance TRx Size

  5. Slide 5: Trulance prescriber base expanding since launch

    TRULANCE PRESCRIBER BASE EXPANDING SINCE LAUNCH 6 Source: IQVIA, Mar – Dec 2017 257 1,145 2,427 3,768 4,949 6,121 7,043 7,974 8,868 9,644 0 2,000 4,000 6,000 8,000 10,000 Cumulative Trulance Prescribers

  6. Slide 6: Majority of Trulance growth coming from patients new to branded prescription treatments

    MAJORITY OF TRULANCE GROWTH COMING FROM PATIENTS NEW TO BRANDED PRESCRIPTION TREATMENTS 7 Nearly 50% of Trulance NRx were new branded Rx therapy starts 43% of Trulance patients have converted from other Rx treatments IQVIA - XPD, weeks ending 3/17 – 12/1. Add on 8% Switch To 43% New Therapy Starts 4

  7. Slide 7: Next steps critical to accelerating growth in 2018

    NEXT STEPS CRITICAL TO ACCELERATING GROWTH IN 2018: Build off momentum from strong 2017 launch and continue to drive the uptake of Trulance Expand opportunity with new IBS-C label - ability to promote important abdominal pain component Leverage strong foundation established with healthcare providers

  8. Slide 8: Next steps critical to accelerating growth in 2018

    NEXT STEPS CRITICAL TO ACCELERATING GROWTH IN 2018: + Build off momentum from strong 2017 launch and continue to drive the uptake of Trulance + Expand opportunity with new IBS-C label - ability to promote important abdominal pain component + Leverage strong foundation established with healthcare pro

Synergy Pharmaceuticals — Leerink Partners Global Healthcare Conference 2018 on 6ix